

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

SECTION 1. IDENTIFICATION

Product name : Lisinopril Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Combustible dust

Reproductive toxicity : Category 1A

Specific target organ
systemic toxicity - repeated
exposure (Oral) : Category 2 (Kidney)

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H360D May damage the unborn child.
H373 May cause damage to organs (Kidney) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

and understood.

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Starch	9005-25-8	≥ 10 - < 20
Lisinopril	83915-83-7	≥ 5 - < 10

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

- | | |
|---|--|
| Most important symptoms and effects, both acute and delayed | : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure if swallowed. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists. |
| Notes to physician | : Treat symptomatically and supportively. |

SECTION 5. FIRE-FIGHTING MEASURES

- | | |
|--|---|
| Suitable extinguishing media | : Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : None known. |
| Specific hazards during fire fighting | : Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides
Metal oxides
Oxides of phosphorus |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area. |
| Special protective equipment for fire-fighters | : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment. |

SECTION 6. ACCIDENTAL RELEASE MEASURES

- | | |
|---|---|
| Personal precautions, protective equipment and emergency procedures | : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations. |
| Environmental precautions | : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for | : Sweep up or vacuum up spillage and collect in suitable |

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

containment and cleaning up container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice.
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
-------------	---------	----------------------------------	--	-------

Lisinopril Formulation

Version 3.4 Revision Date: 06/12/2017 SDS Number: 50025-00008 Date of last issue: 04/28/2017
 Date of first issue: 01/26/2015

Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Lisinopril	83915-83-7	TWA	40 µg/m ³	Merck
		Wipe limit	400 µg/100 cm ²	Merck

Engineering measures : Minimize workplace exposure concentrations.
 Apply measures to prevent dust explosions.
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
 Use with local exhaust ventilation.
 Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m³ - total dust, 5 mg/m³ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m³ - respirable particles, 10 mg/m³ - inhalable particles.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material

: Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the

SAFETY DATA SHEET



Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

- | | | |
|--------------------------|---|---|
| Eye protection | : | Wear the following personal protective equipment:
Safety goggles |
| Skin and body protection | : | Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc). |
| Hygiene measures | : | Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use. |

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- | | | |
|--|---|---|
| Appearance | : | powder |
| Color | : | No data available |
| Odor | : | odorless |
| Odor Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | No data available |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapor pressure | : | No data available |
| Relative vapor density | : | No data available |

SAFETY DATA SHEET



Lisinopril Formulation

Version 3.4	Revision Date: 06/12/2017	SDS Number: 50025-00008	Date of last issue: 04/28/2017 Date of first issue: 01/26/2015
----------------	------------------------------	----------------------------	---

Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Ingredients:

Starch:

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

Acute oral toxicity : LD50 (Mouse): > 5,000 mg/kg

Lisinopril:

Acute oral toxicity : LD50 (Rat): > 20,000 mg/kg

LD50 (Mouse): > 20,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Ingredients:**Lisinopril:**

Species: Rabbit

Result: Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Lisinopril:**

Species: Rabbit

Result: Mild eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Lisinopril:**

Test Type: Maximization Test

Routes of exposure: Dermal

Result: negative

Germ cell mutagenicity

Not classified based on available information.

Ingredients:**Lisinopril:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

: Test Type: In vitro mammalian cell gene mutation test
Species: Chinese hamster lung cells
Result: negative

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

Genotoxicity in vitro : Test Type: Alkaline elution assay
Species: rat hepatocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Ingredients:**Lisinopril:**

Species: Rat
Application Route: Oral
Exposure time: 105 weeks
NOAEL: 90 mg/kg body weight
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
NOAEL: 135 mg/kg body weight
Result: negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

May damage the unborn child.

Ingredients:**Lisinopril:**

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 300 mg/kg body weight
Symptoms: No effects on mating performance.
Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: positive, No teratogenic effects.

Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Symptoms: Total Resorptions / resorption rate.
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 0.1 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Kidney) through prolonged or repeated exposure if swallowed.

Ingredients:**Lisinopril:**

Routes of exposure: Ingestion

Target Organs: Kidney

Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Ingredients:****Lisinopril:**

Species: Rat

LOAEL: < 3,650 mg/kg

Application Route: Oral

Exposure time: 1 y

Target Organs: Kidney

Species: Dog

LOAEL: < 840 mg/kg

Application Route: Oral

Exposure time: 4 Weeks

Target Organs: Kidney

Aspiration toxicity

Not classified based on available information.

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

Experience with human exposure**Ingredients:****Lisinopril:**

Ingestion : Symptoms: Dizziness, Headache, Fatigue, Diarrhea, Nausea, Cough, Lowered blood pressure, electrolyte imbalance
Remarks: May damage the unborn child.

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Ingredients:****Lisinopril:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 20,000 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Fire Hazard
Chronic Health Hazard

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations**Pennsylvania Right To Know**

Calcium Phosphate Dibasic Dihydrate	7789-77-7
D-mannitol	69-65-8
Starch	9005-25-8
Lisinopril	83915-83-7

California Prop. 65

WARNING: This product contains a chemical known in the State of California to cause birth defects or other reproductive harm.

Lisinopril	83915-83-7
------------	------------

California Permissible Exposure Limits for Chemical Contaminants

Starch	9005-25-8
--------	-----------

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SAFETY DATA SHEET




Lisinopril Formulation

Version 3.4 Revision Date: 06/12/2017 SDS Number: 50025-00008 Date of last issue: 04/28/2017
Date of first issue: 01/26/2015

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS® IV:

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits
OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA : 8-hour, time-weighted average
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA : 8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office

Lisinopril Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
3.4	06/12/2017	50025-00008	Date of first issue: 01/26/2015

of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/12/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8